… g, Proposed model of clonal evolution to t-MDS in case 895681; the diagnostic t-MDS …
These mutations would not be randomly distributed but biased (in particular towards C to T/G to A …

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The COG–…

… g/dL (25.6 to 12.0 g/dL) between the first and second magrolimab doses and 20.5 g/dL (24.9
to 15.4 g/dL) … A total of 27.2% of patients had a $ 2 g/dL drop and 10.9% had a $ 3 g/dL drop …

Background TP53 mutations, which are present in 5% to 10% of patients with acute myeloid
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …

Natural killer (NK) cells are innate lymphocytes important for early host defense against
infectious pathogens and surveillance against malignant transformation. Resting murine NK …

BACKGROUND: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and
current knowledge regarding survival in this disease is limited to small series of patients. …

7020 Background: Magrolimab is a monoclonal antibody blocking CD47, a “don’t eat me”
signal overexpressed on cancer cells such as acute myeloid leukemia (AML). This blockade …

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and have
been implicated in the pathogenesis of cancer. In this study, we applied next generation …

… In this study, 59.8% of patients had a Hb level of <9 g/dL at baseline and Hb decreases
were observed most commonly after the first one to two doses, with a ≥3 g/dL drop reported in …

… after mobilization with G-CSF and plerixafor, 9 after G-CSF alone, and 8 cryopreserved
products were infused after mobilization with G-CSF only. Products mobilized with G-CSF and …